載入...
Use of Prednisone With Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
Abiraterone acetate, a prodrug of the CYP17A1 inhibitor abiraterone that blocks androgen biosynthesis, is approved for treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with prednisone or prednisolone 5 mg twice daily. This review evaluates the basis f...
Na minha lista:
| 發表在: | Oncologist |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
AlphaMed Press
2014
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4257741/ https://ncbi.nlm.nih.gov/pubmed/25361624 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0167 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|